POLQ and neoplasm: For the subcutaneous xenograft model, combined treatment with POLQ inhibitors and sulfasalazine, a ferroptosis inducer that inhibits SLC7A11, synergistically suppressed MGC-803 xenograft tumor growth (Fig. 7A–C).